Opinion|Videos|December 12, 2024
Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment
Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.
Advertisement
Episodes in this series
- How frequently are you observing hypertension when treating your patients with trifluridine-tipiracil plus bevacizumab? What is your monitoring and management strategy for hypertension?
- How often do you see patients with hepatic or renal impairment in your clinical practice? What is your dosing strategy for TAS-102 plus bevacizumab for those who have hepatic or renal impairment?
- What are some common toxicities associated with fruquintinib? How do you manage patients who may develop hypertension, hand-foot syndrome, or hepatotoxicity?
- What are some common toxicities associated with regorafenib? How does your clinic manage potential toxicities seen with regorafenib, like hand-foot syndrome?
Advertisement
Related to this article
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
The EMA validated the marketing authorization application for varegacestat in adults with desmoid tumors.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
5